An FDA advisory panel has voted in favor of Moderna booster shots for the same three groups (65+; 18-64 with underlying conditions; 18-64 with workplace exposure) that Pfizer recipients are eligible under.

(More steps remain until the shots start going into arms.)

— Josh Wingrove (@josh_wingrove) October 14, 2021